250 related articles for article (PubMed ID: 37352859)
1. Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup.
Walker LC; Hoya M; Wiggins GAR; Lindy A; Vincent LM; Parsons MT; Canson DM; Bis-Brewer D; Cass A; Tchourbanov A; Zimmermann H; Byrne AB; Pesaran T; Karam R; Harrison SM; Spurdle AB;
Am J Hum Genet; 2023 Jul; 110(7):1046-1067. PubMed ID: 37352859
[TBL] [Abstract][Full Text] [Related]
2. APPLICATION OF THE ACMG/AMP FRAMEWORK TO CAPTURE EVIDENCE RELEVANT TO PREDICTED AND OBSERVED IMPACT ON SPLICING: RECOMMENDATIONS FROM THE CLINGEN SVI SPLICING SUBGROUP.
Walker LC; de la Hoya M; Wiggins GAR; Lindy A; Vincent LM; Parsons MT; Canson DM; Bis-Brewer D; Cass A; Tchourbanov A; Zimmermann H; Byrne AB; Pesaran T; Karam R; Harrison S; Spurdle AB
medRxiv; 2023 Feb; ():. PubMed ID: 36865205
[TBL] [Abstract][Full Text] [Related]
3. Evaluating ClinGen variant curation expert panels' application of PVS1 code.
Wang X; Li H; Luo H; Zou Y; Li H; Qin Y; Song J
Eur J Med Genet; 2024 Feb; 67():104909. PubMed ID: 38199457
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework.
Brnich SE; Abou Tayoun AN; Couch FJ; Cutting GR; Greenblatt MS; Heinen CD; Kanavy DM; Luo X; McNulty SM; Starita LM; Tavtigian SV; Wright MW; Harrison SM; Biesecker LG; Berg JS;
Genome Med; 2019 Dec; 12(1):3. PubMed ID: 31892348
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the impact of in silico predictors on clinical variant classification.
Wilcox EH; Sarmady M; Wulf B; Wright MW; Rehm HL; Biesecker LG; Abou Tayoun AN
Genet Med; 2022 Apr; 24(4):924-930. PubMed ID: 34955381
[TBL] [Abstract][Full Text] [Related]
6. VIP-HL: Semi-automated ACMG/AMP variant interpretation platform for genetic hearing loss.
Peng J; Xiang J; Jin X; Meng J; Song N; Chen L; Abou Tayoun A; Peng Z
Hum Mutat; 2021 Dec; 42(12):1567-1575. PubMed ID: 34428318
[TBL] [Abstract][Full Text] [Related]
7. Variant Classification for Pompe disease; ACMG/AMP specifications from the ClinGen Lysosomal Diseases Variant Curation Expert Panel.
Goldstein JL; McGlaughon J; Kanavy D; Goomber S; Pan Y; Deml B; Donti T; Kearns L; Seifert BA; Schachter M; Son RG; Thaxton C; Udani R; Bali D; Baudet H; Caggana M; Hung C; Kyriakopoulou L; Rosenblum L; Steiner R; Pinto E Vairo F; Wang Y; Watson M; Fernandez R; Weaver M; Clarke L; Rehder C
Mol Genet Metab; 2023; 140(1-2):107715. PubMed ID: 37907381
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion.
Abou Tayoun AN; Pesaran T; DiStefano MT; Oza A; Rehm HL; Biesecker LG; Harrison SM;
Hum Mutat; 2018 Nov; 39(11):1517-1524. PubMed ID: 30192042
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels.
Kanavy DM; McNulty SM; Jairath MK; Brnich SE; Bizon C; Powell BC; Berg JS
Genome Med; 2019 Nov; 11(1):77. PubMed ID: 31783775
[TBL] [Abstract][Full Text] [Related]
10. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria.
Pejaver V; Byrne AB; Feng BJ; Pagel KA; Mooney SD; Karchin R; O'Donnell-Luria A; Harrison SM; Tavtigian SV; Greenblatt MS; Biesecker LG; Radivojac P; Brenner SE;
Am J Hum Genet; 2022 Dec; 109(12):2163-2177. PubMed ID: 36413997
[TBL] [Abstract][Full Text] [Related]
11. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.
Lee K; Krempely K; Roberts ME; Anderson MJ; Carneiro F; Chao E; Dixon K; Figueiredo J; Ghosh R; Huntsman D; Kaurah P; Kesserwan C; Landrith T; Li S; Mensenkamp AR; Oliveira C; Pardo C; Pesaran T; Richardson M; Slavin TP; Spurdle AB; Trapp M; Witkowski L; Yi CS; Zhang L; Plon SE; Schrader KA; Karam R
Hum Mutat; 2018 Nov; 39(11):1553-1568. PubMed ID: 30311375
[TBL] [Abstract][Full Text] [Related]
12. Clinical Interpretation of Sequence Variants.
Zhang J; Yao Y; He H; Shen J
Curr Protoc Hum Genet; 2020 Jun; 106(1):e98. PubMed ID: 32176464
[TBL] [Abstract][Full Text] [Related]
13. Adapting the ACMG/AMP variant classification framework: A perspective from the ClinGen Hemoglobinopathy Variant Curation Expert Panel.
Kountouris P; Stephanou C; Lederer CW; Traeger-Synodinos J; Bento C; Harteveld CL; Fylaktou E; Koopmann TT; Halim-Fikri H; Michailidou K; Nfonsam LE; Waye JS; Zilfalil BA; Kleanthous M;
Hum Mutat; 2022 Aug; 43(8):1089-1096. PubMed ID: 34510646
[TBL] [Abstract][Full Text] [Related]
14. Specifications of the ACMG/AMP variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel.
Burdon KP; Graham P; Hadler J; Hulleman JD; Pasutto F; Boese EA; Craig JE; Fingert JH; Hewitt AW; Siggs OM; Whisenhunt K; Young TL; Mackey DA; Dubowsky A; Souzeau E
Hum Mutat; 2022 Dec; 43(12):2170-2186. PubMed ID: 36217948
[TBL] [Abstract][Full Text] [Related]
15. Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss.
Patel MJ; DiStefano MT; Oza AM; Hughes MY; Wilcox EH; Hemphill SE; Cushman BJ; Grant AR; Siegert RK; Shen J; Chapin A; Boczek NJ; Schimmenti LA; Nara K; Kenna M; Azaiez H; Booth KT; Avraham KB; Kremer H; Griffith AJ; Rehm HL; Amr SS; Tayoun ANA;
Genet Med; 2021 Nov; 23(11):2208-2212. PubMed ID: 34230634
[TBL] [Abstract][Full Text] [Related]
16. Refinement of the assignment to the ACMG/AMP BS3 and PS3 criteria of eight
Caleca L; Radice P
Front Oncol; 2023; 13():1146604. PubMed ID: 37168384
[TBL] [Abstract][Full Text] [Related]
17. ClinGen's RASopathy Expert Panel consensus methods for variant interpretation.
Gelb BD; Cavé H; Dillon MW; Gripp KW; Lee JA; Mason-Suares H; Rauen KA; Williams B; Zenker M; Vincent LM;
Genet Med; 2018 Nov; 20(11):1334-1345. PubMed ID: 29493581
[TBL] [Abstract][Full Text] [Related]
18. Variant curation expert panel recommendations for RYR1 pathogenicity classifications in malignant hyperthermia susceptibility.
Johnston JJ; Dirksen RT; Girard T; Gonsalves SG; Hopkins PM; Riazi S; Saddic LA; Sambuughin N; Saxena R; Stowell K; Weber J; Rosenberg H; Biesecker LG
Genet Med; 2021 Jul; 23(7):1288-1295. PubMed ID: 33767344
[TBL] [Abstract][Full Text] [Related]
19. ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.
Luo X; Feurstein S; Mohan S; Porter CC; Jackson SA; Keel S; Chicka M; Brown AL; Kesserwan C; Agarwal A; Luo M; Li Z; Ross JE; Baliakas P; Pineda-Alvarez D; DiNardo CD; Bertuch AA; Mehta N; Vulliamy T; Wang Y; Nichols KE; Malcovati L; Walsh MF; Rawlings LH; McWeeney SK; Soulier J; Raimbault A; Routbort MJ; Zhang L; Ryan G; Speck NA; Plon SE; Wu D; Godley LA
Blood Adv; 2019 Oct; 3(20):2962-2979. PubMed ID: 31648317
[TBL] [Abstract][Full Text] [Related]
20. [The updates of the ACMG variant interpretation guidelines affect the pathogenicity determination of
Wu KL; Li J; Wang HY; Wang QJ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 May; 59(5):455-463. PubMed ID: 38811176
[No Abstract] [Full Text] [Related]
[Next] [New Search]
